ImClone Founder Harlan Waksal Comments on Senesco's Merger With Fabrus During Exclusive RedChip TV Interview Print
GlobeNewswire
Wednesday, 08 January 2014 03:15

ORLANDO, Fla.--RedChip Companies, Inc. ("RedChip"), an international small-cap research, investor relations, and media company, today announced that Dr. Harlan Waksal, chairman of Senesco Technologies, Inc. (OTCQB:SNTI), a clinical-stage biotech company specializing in cancer therapeutics, was recently interviewed on "The RedChip Money Report: Small Stocks Big Money."

During the interview with RedChip TV host Dave Gentry, Dr. Waksal provides comments on Senesco's recently announced merger with Fabrus, Inc., a privately-held, biotechnology company focused on expanding the clinical impact of antibodies by addressing drug targets resistant to traditional antibody discovery methods.

The interview includes comments from Dr. Waksal about the unique and complimentary approach of Fabrus' technology, the benefits of antibody targeting, big-pharma agreements, and near-term clinical trials.

The full interview is available online at http://www.youtube.com/watch?v=BtS__rTrZAE

Dr. Waksal has been a director of Senesco since October 2008 and chairman of the board of directors since June 2009. From July 2003 to present, Dr. Waksal has been the President and Sole Proprietor of Waksal Consulting L.L.C., which provides strategic business and clinical development counsel to biotechnology companies. From July 2011 to present, he served as the Executive Vice-President, Business and Scientific Affairs of Acasti Pharma, Inc., which is a subsidiary of Neptune Technologies & Bioresources, Inc. Dr. Waksal co-founded the biotechnology company ImClone Systems Inc. in 1984. Dr. Waksal received a Bachelor of Arts in Biology from Oberlin College and an M.D. from Tufts University School of Medicine.

About RedChip Companies, Inc.

RedChip Companies, an Inc. 5000 company, is an international small-cap research, investor relations, and media company headquartered in Orlando, Florida; with affiliate offices in San Francisco, Pittsburgh, and Seoul. RedChip delivers concrete, measurable results for its clients through its extensive global network of small-cap institutional and

Error. Page cannot be displayed. Please contact your service provider for more details. (24)

retail investors. RedChip has developed the most comprehensive platform of products and
services for small-cap companies, including: RedChip Research™, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, Virtual Conferences, "The RedChip Money Report: Small Stocks Big Money"™ television show, Shareholder Intelligence, Strategic Marketing, Crisis Management, Social Media and
Blogging Services, and Webcasts. To learn more about RedChip's products and services, please visit: http://www.redchip.com/visibility/productsandservices.asp.

"Discovering Tomorrow's Blue Chips Today"™

CONTACT: Jon Cunningham          RedChip Companies, Inc.          Tel: 1-800-RED-CHIP (733-2447), ext. 107          Email: info@redchip.com

RedChip Companies Inc. Logo




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1